Cargando…
Clinical Cancer Therapy by NK Cells via Antibody-Dependent Cell-Mediated Cytotoxicity
Natural killer (NK) cells are powerful effector cells that can be directed to eliminate tumor cells through tumor-targeted monoclonal antibodies (mAbs). Some tumor-targeted mAbs have been successfully applied in the clinic and are included in the standard of care for certain malignancies. Strategies...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3110303/ https://www.ncbi.nlm.nih.gov/pubmed/21660134 http://dx.doi.org/10.1155/2011/379123 |
_version_ | 1782205513745825792 |
---|---|
author | Alderson, Kory L. Sondel, Paul M. |
author_facet | Alderson, Kory L. Sondel, Paul M. |
author_sort | Alderson, Kory L. |
collection | PubMed |
description | Natural killer (NK) cells are powerful effector cells that can be directed to eliminate tumor cells through tumor-targeted monoclonal antibodies (mAbs). Some tumor-targeted mAbs have been successfully applied in the clinic and are included in the standard of care for certain malignancies. Strategies to augment the antitumor response by NK cells have led to an increased understanding of how to improve their effector responses. Next-generation reagents, such as molecularly modified mAbs and mAb-cytokine fusion proteins (immunocytokines, ICs) designed to augment NK-mediated killing, are showing promise in preclinical and some clinical settings. Continued research into the antitumor effects induced by NK cells and tumor-targeted mAbs suggests that additional intrinsic and extrinsic factors may influence the antitumor response. Therefore more research is needed that focuses on evaluating which NK cell and tumor criteria are best predictive of a clinical response and which combination immunotherapy regimens to pursue for distinct clinical settings. |
format | Online Article Text |
id | pubmed-3110303 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-31103032011-06-09 Clinical Cancer Therapy by NK Cells via Antibody-Dependent Cell-Mediated Cytotoxicity Alderson, Kory L. Sondel, Paul M. J Biomed Biotechnol Review Article Natural killer (NK) cells are powerful effector cells that can be directed to eliminate tumor cells through tumor-targeted monoclonal antibodies (mAbs). Some tumor-targeted mAbs have been successfully applied in the clinic and are included in the standard of care for certain malignancies. Strategies to augment the antitumor response by NK cells have led to an increased understanding of how to improve their effector responses. Next-generation reagents, such as molecularly modified mAbs and mAb-cytokine fusion proteins (immunocytokines, ICs) designed to augment NK-mediated killing, are showing promise in preclinical and some clinical settings. Continued research into the antitumor effects induced by NK cells and tumor-targeted mAbs suggests that additional intrinsic and extrinsic factors may influence the antitumor response. Therefore more research is needed that focuses on evaluating which NK cell and tumor criteria are best predictive of a clinical response and which combination immunotherapy regimens to pursue for distinct clinical settings. Hindawi Publishing Corporation 2011 2011-05-24 /pmc/articles/PMC3110303/ /pubmed/21660134 http://dx.doi.org/10.1155/2011/379123 Text en Copyright © 2011 K. L. Alderson and P. M. Sondel. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Alderson, Kory L. Sondel, Paul M. Clinical Cancer Therapy by NK Cells via Antibody-Dependent Cell-Mediated Cytotoxicity |
title | Clinical Cancer Therapy by NK Cells via Antibody-Dependent Cell-Mediated Cytotoxicity |
title_full | Clinical Cancer Therapy by NK Cells via Antibody-Dependent Cell-Mediated Cytotoxicity |
title_fullStr | Clinical Cancer Therapy by NK Cells via Antibody-Dependent Cell-Mediated Cytotoxicity |
title_full_unstemmed | Clinical Cancer Therapy by NK Cells via Antibody-Dependent Cell-Mediated Cytotoxicity |
title_short | Clinical Cancer Therapy by NK Cells via Antibody-Dependent Cell-Mediated Cytotoxicity |
title_sort | clinical cancer therapy by nk cells via antibody-dependent cell-mediated cytotoxicity |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3110303/ https://www.ncbi.nlm.nih.gov/pubmed/21660134 http://dx.doi.org/10.1155/2011/379123 |
work_keys_str_mv | AT aldersonkoryl clinicalcancertherapybynkcellsviaantibodydependentcellmediatedcytotoxicity AT sondelpaulm clinicalcancertherapybynkcellsviaantibodydependentcellmediatedcytotoxicity |